[The clinical efficacy of ticarcillin/clavulanate in severe pneumonia].
Efficacy of ticarcillin/clavulanate was studied in the treatment of 11 patients with severe community- and hospital-acquired pneumonia in an open controlled trial. The drug was administered in a dose of 3.1 g every 4 or 6 hours depending on the infection severity. When pneumonia was due to Pseudomonas aeruginosa, amikacin was additionally used. The positive clinical effect of ticarcillin/clavulanate was stated in 73 per cent of the patients. The pathogen eradication was stated in all the patients. However, in 2 cases superinfection due to P.aeruginosa developed. Mild adverse effects were observed in 2 cases. It is concluded that ticarcillin/clavulanate is highly efficient in the treatment of patients with severe or complicated pneumonia. In cases with ventilator-associated pneumonia it is advisable to use ticarcillin/clavulanate in combination with an aminoglycoside.
Iakovlev
S V
SV
I. M. Sechenov Moscow Medical Academy, Municipal Clinical Hospital No. 7.
Dvoretskiĭ
L I
LI
Shakhova
T V
TV
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000009:adverse effects; D017714:Community-Acquired Infections / Q000150:complications / Q000188:drug therapy; D003428:Cross Infection / Q000150:complications / Q000188:drug therapy; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008169:Lung Abscess / Q000188:drug therapy / Q000209:etiology; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000150:complications / Q000188:drug therapy*; D013982:Ticarcillin / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
D002969:Clavulanic Acids; C043215:ticarcillin-clavulanic acid; D013982:Ticarcillin